Eli Lilly and (LLY)
822.47
-2.29 (-0.28%)
At close: Mar 18, 2025, 3:59 PM
-0.28% (1D)
| Bid | 818.07 |
| Market Cap | 779.69B |
| Revenue (ttm) | 47.25B |
| Net Income (ttm) | 11.11B |
| EPS (ttm) | 11.71 |
| PE Ratio (ttm) | 70.24 |
| Forward PE | 35.77 |
| Analyst | Buy |
| Ask | 825.45 |
| Volume | 1,899,860 |
| Avg. Volume (20D) | 3,672,789 |
| Open | 833.42 |
| Previous Close | 824.76 |
| Day's Range | 812.62 - 836.29 |
| 52-Week Range | 711.40 - 972.53 |
| Beta | 0.34 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer ...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Jun 1, 1972
Employees 47,000
Stock Exchange NYSE
Ticker Symbol LLY
Website https://www.lilly.com
Analyst Forecast
According to 26 analyst ratings, the average rating for LLY stock is "Buy." The 12-month stock price forecast is $1001, which is an increase of 21.71% from the latest price.
Stock ForecastsNext Earnings Release
Eli Lilly and is scheduled to release its earnings on May 1, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-6.59%
Eli Lily shares are trading lower after the compan...
Unlock content with
Pro Subscription
2 months ago
+3.71%
Ely Lilly shares are trading higher after the FDA approved the company's Zepbound, a weight loss drug designed to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
